Questions and Concerns

The global next-generation targeted oncology drug market size was valued at USD 15.26 billion in 2025 and is expected to reach USD 40.85 billion by 2033, at a CAGR of 13.10% during the forecast period

The market growth is largely fueled by the rising global burden of cancer, increasing demand for precision and personalized therapies, and rapid advancements in biotechnology such as CAR-T, mRNA platforms, and bispecific antibodies, driving innovation in targeted treatment approaches

The global smart biopsy devices market size was valued at USD 3.04 billion in 2025 and is expected to reach USD 4.88 billion by 2033, at a CAGR of 6.12% during the forecast period

The market growth is largely fueled by the increasing adoption of advanced diagnostic technologies and the growing demand for early and accurate cancer detection, leading to greater utilization of smart biopsy devices across hospitals, diagnostic centers, and oncology clinics

Furthermore, rising investments in precision medicine, increasing prevalence of cancer, and the growing integration of imaging-guided and minimally invasive biopsy technologies are establishing smart biopsy devices as essential tools in modern diagnostic procedures. These converging factors are accelerating the uptake of Smart Biopsy Devices solutions, thereby significantly boosting the industry's growth